Biogen takes territorial rights to Stoke’s Dravet program: Deals Report

More than two years into the tenure of CEO Christopher Viehbacher, Biogen is continuing to reshape itself via dealmaking. In its latest move, the big biotech has obtained rights outside of North America to an antisense therapy for Dravet syndrome, a rare seizure disorder, from Stoke.

Biogen Inc. (NASDAQ:BIIB) said Tuesday that it is paying Stoke Therapeutics Inc. (NASDAQ:STOK) $165 million up front for rights to zorevunersen, an antisense oligonucleotide targeting SCN1A. The deal, which excludes rights in the U.S., Canada and Mexico, includes another $385 million in milestones, plus royalties; the parties have agreed to split development costs 70/30, with Stoke shouldering the larger load...